Corporate Profile

Viridian Therapeutics is a biotechnology company advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies. Viridian’s most advanced program, VRDN-001, is an anti-insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody in development for thyroid eye disease (TED), a debilitating auto-immune disease that causes inflammation and fibrosis of the orbital tissues surrounding the eye, leading to proptosis, or bulging of the eyes, redness and swelling, diplopia (double vision), pain, and potential blindness. Current treatments options remain limited and burdensome. In August 2022, the Company announced positive initial clinical data from ongoing Phase 1/2 Trial evaluating VRDN-001 in patients with TED. Access the news release and data deck.

The Company is based in Waltham, Massachusetts, with offices in Boulder and New York City.

Stock Information

Viridian Therapeutics (NASDAQ - VRDN)

Data Provided by Refinitiv. Minimum 15 minutes delayed.


Viridian Therapeutics
221 Crescent St.
Suite 401
Waltham, MA 02453
P: 617 272-4600
F: 617 272-4601

Corporate Presentation

September 6, 2022
Viridian Corporate Presentation
Download PDF